Navigation Links
ResMed Inc. Announces Exchange Rate For Upcoming Dividend Payment
Date:11/21/2012

SAN DIEGO, Nov. 21, 2012 /PRNewswire/ -- ResMed Inc. (NYSE: RMD) today announced that the dividend to be paid on December 18, 2012, to holders of Chess Depositary Instruments (CDIs) trading on the Australian Securities Exchange will be Australian dollar $0.01636 per CDI. 

(Logo: http://photos.prnewswire.com/prnh/20100203/RESMEDLOGO)

ResMed previously declared a quarterly dividend of US dollar $0.17 per share, which had a record date of November 20, 2012, and will be payable on December 18, 2012.  The dividend will be paid in US currency to holders of its common stock trading on the New York Stock Exchange (NYSE). 

The dividend paid in Australian currency to CDI holders reflects the exchange rate on the record date, which was US dollars $1.0389 for each Australian dollar $1.00, and reflects the 10:1 ratio between CDIs and US common shares listed on the NYSE. 

About ResMed
ResMed is a global leader in the development, manufacturing and marketing of medical products for the diagnosis, treatment and management of respiratory disorders, with a focus on sleep-disordered breathing. The company is dedicated to developing innovative products to improve the lives of those who suffer from these conditions and to increasing awareness among patients and healthcare professionals of the potentially serious health consequences of untreated sleep-disordered breathing. For more information on ResMed, visit www.resmed.com.

Further information can be obtained by contacting Brett Sandercock at ResMed Limited, Sydney, on (+612) 8884-2090; or by visiting the Company's multilingual Website at www.resmed.com

Statements contained in this release that are not historical facts are "forward-looking" statements as contemplated by the Private Securities Litigation Reform Act of 1995. These forward-looking statements, including statements regarding the Company's future revenue, earnings or expenses, new product development and new markets for the Company's products, are subject to risks and uncertainties, which could cause actual results to materially differ from those projected or implied in the forward-looking statements. Those risks and uncertainties are discussed in the Company's Annual Report on Form 10-K for its most recent fiscal year and in other reports the Company files with the U.S. Securities & Exchange Commission.  Those reports are available on the Company's Website.


'/>"/>
SOURCE ResMed Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. ResMed Inc. Announces Record Financial Results for the Quarter Ended September 30, 2012
2. ResMed Inc. Announces Record Financial Results For The Quarter And Twelve Months Ended June 30, 2012
3. ResMed Announces Conference Call And Webcast To Discuss Fourth Quarter And Fiscal Year-End 2012 Results
4. ResMed Launches Narvalâ„¢ CC Mandibular Repositioning Device in the US
5. ResMed Inc. Announces Plan To Initiate Dividend And Update On Chief Executive Officer Succession
6. AspenBio Pharma Announces Closing of Public Offering of 1,946,000 Shares of Common Stock
7. Vasomedical Announces Financial Results for the Third Quarter of 2012
8. Proteonomix, Inc. Announces Screening of Patients with End Stage Liver Disease in its Clinical Study of UMK-121
9. Ohr Pharmaceutical Announces Additions to Ophthalmic Scientific Advisory Board
10. NeuroDerm Announces Enrollment in a Phase 1 Study of ND0612, a Continuous Levodopa/Carbidopa Drug for the Treatment of Parkinsons Disease
11. ShangPharma Announces Third Quarter 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... , Feb. 11, 2016 The primary goal ... future adoption patterns on the usage of liquid biopsy. ... following: - Timeframe of liquid biopsy adoption ... cfDNA and Evs—by organization type - Sample inflow to ... blood, saliva, stool, serum, and so on. - Correlation ...
(Date:2/11/2016)... 2016 PRO-DEX, INC. (NasdaqCM: PDEX) today announced financial ... 2015. The Company also filed its Quarterly Report on Form ... the Securities and Exchange Commission today. --> ... --> --> Net sales for ... or 95%, to $5.4 million from $2.8 million for the ...
(Date:2/11/2016)... , Feb. 11, 2016  Kindred Biosciences, Inc. ... saving and improving the lives of pets, today announced ... of the New Animal Drug Application (NADA) for Zimeta™ ... field study (KB0120) of Zimeta for the control of ... Company. --> --> ...
Breaking Medicine Technology:
(Date:2/12/2016)... ... February 12, 2016 , ... The ThedaCare ... San Francisco General Hospital on April 5-7. The series is a multi-day, multi-workshop ... habits. The workshops cover a broad range of topics, including coaching skills, the ...
(Date:2/12/2016)... ... 2016 , ... Fisher House Foundation Chairman and CEO Kenneth Fisher joined Governor ... Alliance president Scott Bensing, and Peggy Kearns Director, VA Southern Nevada Healthcare System yesterday ... This will be the first Fisher House in Nevada, and will provide free lodging ...
(Date:2/12/2016)... ... ... Vail knee specialist Robert LaPrade, MD, PhD was named one of ... of physicians establishing, leading and partnering with ambulatory surgery centers across the United States. ... also known as an ASC, is a modern health care facility focused on providing ...
(Date:2/12/2016)... ... ... Donor Network West, the organ procurement organization that heals lives through organ ... Regional Medical Center. Under the collaboration, the first of its kind, specific organ donors ... certain time frame for donor families for the recovery of organs. , Organ ...
(Date:2/12/2016)... ... 12, 2016 , ... J Thomas & Associates Insurance Agency, ... to act as Agents of Change in the community, announces a new partnership ... to fulfill immediate needs and help them move into permanent housing. Donations to ...
Breaking Medicine News(10 mins):